Europe Throat Cancer Diagnostics Market is expected to reach USD 721.95 million by 2030

Market Definition

Throat cancer is a type of cancer that forms in tissues of the pharynx (the hollow tube inside the neck that starts behind the nose and ends at the top of the windpipe and esophagus). Throat cancer includes cancer of the nasopharynx (the upper part of the throat behind the nose), the oropharynx (the middle part of the pharynx), and the hypopharynx (the bottom part of the pharynx). Cancer of the larynx (voice box) may also be included as a type of throat cancer. Most throat cancers are squamous cell carcinomas (cancer that begins in thin, flat cells that look like fish scales), also called pharyngeal cancer.

Europe Throat Cancer Diagnostics Market Dynamics
Drivers

Growing prevalence of throat cancer
Throat cancer is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. The rising use of cigarettes and other tobacco substitutes may be partially responsible for the rise in the prevalence of throat cancer.

People affected with throat cancer can see the symptoms such as a cough, changes in their voice, such as hoarseness or not speaking clearly, difficulty swallowing, ear pain, a lump or sore that doesn't heal, a sore throat, and weight loss among others.

GET FULL REPORT: https://www.databridgemarketresearch.com/reports/europe-throat-cancer-diagnostics-market

Novel technological advancements in throat cancer diagnostics
Radiotherapy has an integral role in the treatment of throat cancer. Although radiotherapy has the potential to cure patients with advanced diseases, it also carries the potential for significant long-term morbidity. New technologies in the setting of head and neck radiotherapy are emerging, which have the potential to increase the cure rate and decrease toxicity. These new technologies include improved radiotherapy treatment design (intensity-modulated radiation therapy) and improved planning and implementation (image-guided radiation therapy).

Restraints

Late diagnosis and poor prognosis of throat cancer
Cancer is the leading cause of death worldwide. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, the late patient diagnosis will lead to the growth of cancerous tissue, worsening the cancer condition. The main cause of delayed presentation is a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.

Thus, the late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Europe throat cancer diagnostics market.

High cost for the installation of diagnostic devices

Cancer diagnostics have become increasingly expensive due to the growing number of throat cancer patients and the rising prices of medical devices. The modern technological devices used in cancer diagnosis also play a significant role in the high prices of cancer diagnostics, providing a definitive diagnosis for cancer in thyroid nodules with high accuracy. Therefore, the high cost of diagnostics procedures for throat cancers is hampering the market's growth.

The diagnostic products or devices which are used in the detection of cancer are becoming advanced. However, the procedure for cancer diagnostics is also costly, which hampers the growth of the throat cancer diagnostics market because the devices used in the process of cancer diagnosis are getting more expensive for the early detection of cancerous tissue, which results in to increase in the cost of diagnostics procedure.

Recent Developments

In August 2022, F. Hoffmann-La Roche Ltd, announced the launch of the Digital LightCycler System, Roche's first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. This has helped the company to increase its Europe presence in the market
In March 2021, Hologic, Inc. announced that the company had acquired Diagenode, a privately held Globalan developer and manufacturer of molecular diagnostic assays and epigenetics products. This further strengthens the molecular diagnostics business in the Europe market

Some of the major players operating in the Europe throat cancer diagnostics market are F. Hoffmann-La Roche Ltd., Abbott., Illumina, QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Inc. Merck KGaA., Hologic, Inc., General Electric Company, Siemens Healthcare GmbH, B.D, Myriad Genetics, Inc., Diasorin S.P.A, Koninklijke Philips N.V., Beijing O&D Biotech Co., Ltd, PlexBio Co, Ltd., FUJIFILM Corporation, Canon Inc., FONAR Corp., Medonica Co. LTD, MinFound Medical Systems Co, Sternmed Gmbh, Time Medical Holding., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., among others.

MORE LINKS:

https://dbmrbuisness.blogspot.com/2023/09/middle-east-and-africa-medical-device.html

https://dbmrbuisness.blogspot.com/2023/09/north-america-medical-device-testing.html

https://dbmrbuisness.blogspot.com/2023/09/global-expression-vectors-market-would.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.